Related Experiment Video
Updated: Jun 12, 2025

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
Published on: March 22, 2012
Pulmonary infection by Lophomonas spp. and Aspergillus spp. in a B-cell acute lymphocytic leukemia patient from Chile
Isabel Iturrieta-González1, Enzo Moenen-Locoz2, Alejandro Hidalgo3
1Department of Preclinic Sciences, Medicine Faculty, Laboratory of Infectology and Clinical Immunology, Center of Excellence in Translational Medicine-Scientific and Technological Nucleus (CEMT-BIOREN), Universidad de La Frontera, Temuco 4810296, Chile; Jeffrey Modell Center of Diagnosis and Research in Primary Immunodeficiencies, Center of Excellence in Translational Medicine, Medicine Faculty, Universidad de La Frontera, Temuco 4810296, Chile.
Abstract:
The flagellated protozoan Lophomonas spp. is a commensal microorganism found in the intestinal tracts of cockroaches, termites, mites, and certain birds. It is the causative agent of a rare infection in humans called lophomoniasis, primarily affecting the lungs and mainly immunocompromised individuals. This parasitosis is transmitted to humans by air or through ingestion of the cystic forms of the parasite. We describe the case of a 50-year-old patient treated at a tertiary hospital in southern Chile with a history of B-cell acute lymphocytic leukemia. Radiological findings, along with increased levels of inflammatory parameters and galactomannan antigen in serum and Bronchoaveolar Lavage (BAL) raised the suspicion of a pulmonary infection. Microscopic study of BAL revealed oval to pyriform cells with mobile flagella at the anterior end, which were identified as Lophomonas spp. trophozoites, which based on EORTC/MSG criteria were associated with diagnosis of a probable pulmonary aspergillosis. Lophomoniasis was treated with metronidazole (500 mg IV every 8 h) for 14 days and pulmonary aspergillosis required a combination of fluconazole, voriconazole, anidulafungin, liposomal amphotericin B and isavuconazole. The patient responded favorably and was discharged after 95 days of hospitalization. This case highlights the importance of recognizing lophomoniasis as a parasitic infection in respiratory samples from immunocompromised patients who present pulmonary symptoms, especially those who do not respond satisfactorily to conventional antimicrobial treatments. Further research is needed to understand the various sources of Lophomonas spp. infection and develop infection prevention strategies particularly for high-risk patients.
Insights
Lophomoniasis, a rare parasitic lung infection, was diagnosed in an immunocompromised patient. Prompt identification and treatment with metronidazole led to a favorable outcome, highlighting the need for awareness in respiratory samples.
Area of Science:
- Medical Parasitology
- Infectious Diseases
- Clinical Microbiology
Background:
- Lophomonas spp. are flagellated protozoa, typically commensals in arthropods and birds.
- Lophomoniasis is a rare human infection, primarily affecting the lungs in immunocompromised individuals.
- Transmission occurs via airborne or ingested cystic forms, posing a risk to vulnerable populations.
Observation:
- A 50-year-old patient with B-cell acute lymphocytic leukemia presented with pulmonary symptoms.
- Radiological and laboratory findings suggested pulmonary infection, initially suspected as aspergillosis.
- Microscopic examination of Bronchoalveolar Lavage (BAL) revealed Lophomonas spp. trophozoites.
Findings:
- The case presented a dual diagnosis of lophomoniasis and probable pulmonary aspergillosis.
- Lophomoniasis was treated with metronidazole, while pulmonary aspergillosis required a combination antifungal regimen.
- The patient showed a positive response to treatment and was discharged after 95 days.
Implications:
- This case underscores the importance of identifying Lophomonas spp. in respiratory samples from immunocompromised patients with pulmonary symptoms.
- Recognizing lophomoniasis is crucial, especially in cases unresponsive to standard antimicrobial therapies.
- Further research is needed to elucidate Lophomonas spp. sources and develop effective prevention strategies for high-risk individuals.
More Related Videos
09:52Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
07:21Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
Published on: June 23, 2019
Related Concept Videos
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...